Abstract: In some embodiments, an apparatus includes an electrical connector having a side wall defining a lumen and an elongate opening. The lumen is configured to receive at least a conductive portion of an electronic implant. The elongate opening divides the side wall into a first portion and a second portion. The first portion of the side wall is configured to move relative to the second portion of the side wall between a first position and a second position. The first portion of the side wall is electrically conductive and includes a protrusion. The protrusion is configured to contact the conductive portion of the electronic implant such that the conductive portion of the electronic implant is electrically coupled to the first portion of the side wall when the first portion of the side wall is in the second position.

Abstract: The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.

Abstract: In some embodiments, an apparatus includes an electrical connector having a side wall defining a lumen and an elongate opening. The lumen is configured to receive at least a conductive portion of an electronic implant. The elongate opening divides the side wall into a first portion and a second portion. The first portion of the side wall is configured to move relative to the second portion of the side wall between a first position and a second position. The first portion of the side wall is electrically conductive and includes a protrusion. The protrusion is configured to contact the conductive portion of the electronic implant such that the conductive portion of the electronic implant is electrically coupled to the first portion of the side wall when the first portion of the side wall is in the second position.

Abstract: An apparatus and method for an electrical stimulation lead having a selectively variable length. In an embodiment of the invention, an apparatus includes a conducting element, a stimulating electrode, a pickup electrode and a sheath. The conductive element has a proximal end, a distal end and a length which is defined between the proximal and distal ends. The stimulating electrode is coupled to the distal end of the conductive element and the pickup electrode is coupled to the proximal end of the conductive element. The sheath of the apparatus is configured to enclose at least a portion of the conductive element. The sheath has a reconfigurable portion that is able to move between a first configuration and a second configuration. The sheath has a first length when in the first configuration and a second length when in the second configuration.

Abstract: Pharmaceutical compositions of the active substances glimepiride with metformin or its salts such as hydrochloride, succinate, furmarate, etc. are useful to control blood glucose in patients with type 2 diabetes. To prove the effectiveness of the combination, clinical studies were conducted that demonstrated the existence of not only an additive effect, but also a synergistic effect of the two drugs compared with monotherapy using only one of the drugs used in combination. In consequence, the combination may be used as an effective and safe therapy to control blood glucose in patients with type 2 diabetes, using different proportions of the active substances in combinations suitable for the needs of different patients.

Abstract: The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.